| Sep 4 |
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt
|
| Aug 14 |
SeaStar Medical Holding GAAP EPS of -$1.03
|
| Aug 14 |
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
|
| Aug 13 |
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
|
| Jul 23 |
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
|
| Jul 17 |
Nuwellis reports first commercial sale of Quelimmune therapy to Cincinnati Children’s
|
| Jul 17 |
Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s
|
| Jul 16 |
CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial
|
| Jul 12 |
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
|
| Jul 11 |
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
